1	Title: Cutaneous Leishmania mexicana Infections in the United States: Defining Strains
2	Through Endemic Human Pediatric Cases in Northern Texas
3	
4	Authors: Binita Nepal, Ph.D. ^{1, 2} ; Clare McCormick-Baw, M.D., Ph.D. ³ ; Karisma Patel,
5	Pharm. D. ¹ ; Sarah Firmani, Pharm. D. ¹ ; Dawn M. Wetzel, M.D., Ph.D. ^{1, 2, *}
6	
7	Affiliations: Departments of ¹ Pediatrics, ² Biochemistry, and ³ Pathology, University of
8	Texas Southwestern Medical Center
9	
10	*Corresponding author: Dawn M. Wetzel, M.D., Ph.D., Department of Pediatrics and
11	Biochemistry, University of Texas Southwestern Medical Center, 5323 Harry Hines
12	Blvd, Dallas, TX 75390; phone 214-645-9510; fax 214-648-2961; email:
13	dawn.wetzel@utsouthwestern.edu
14	
15	Running title: Endemic leishmaniasis in the United States
16	
17	Keywords: cutaneous, Leishmania mexicana, leishmaniasis, pediatrics, parasitology,
18	Texas
19	
20	Abbreviations: 6 phosphogluconate dehydrogenase (6PGD), Centers for Disease
21	Control and Prevention (CDC), Infectious Diseases (ID), Infectious Disease Society of
22	America (IDSA), malate dehydrogenase (MDH), mannose phosphate isomerase (MPI),
23	multi-locus sequence analysis (MLSA), polymerase chain reaction (PCR), University of
24	Texas Southwestern Medical Center (UTSW), United States (US)
25	
26	Word counts: Manuscript 1940/2000; Abstract 248/250; Importance 144/150

27 ABSTRACT

Over a six-month span, three patients under five years old with cutaneous leishmaniasis 28 presented to the Pediatric Infectious Diseases Clinic at the University of Texas 29 Southwestern Medical Center/Children's Health Dallas. None had traveled outside of 30 the United States (US); all had confirmed *L. mexicana* infections by PCR. We provide 31 32 case descriptions and images to increase the awareness of this disease among US physicians and scientists. Two patients responded to fluconazole, but one required 33 topical paromomycin. Combining these cases with guidelines and our literature review, 34 35 we suggest that: 1) higher doses (ten-twelve mg/kg/day) of fluconazole should be considered in young children to maximize likelihood and rapidity of response and 2) 36 patients should transition to alternate agents if they do not respond to high-dose 37 fluconazole within six weeks. Furthermore, and of particular interest to the broad 38 microbiology community, we used samples from these cases as a proof-of-concept to 39 40 propose a mechanism to strain-type US-endemic *L. mexicana*. For our analysis, we sequenced three housekeeping genes and the internal transcribed sequence 2 of the 41 ribosomal RNA gene. We identified genetic changes that not only allow us to distinguish 42 43 US-based L. mexicana strains from strains found in other areas of the Americas, but also establish polymorphisms that differ between US isolates. These techniques will 44 45 allow documentation of genetic changes in this parasite as its range expands. Hence, 46 our cases of cutaneous leishmaniasis provide significant evolutionary, treatment and public health implications as climate change increases exposure to formerly tropical 47 diseases in previously non-endemic areas. 48

50 **IMPORTANCE**

Leishmaniasis is a parasitic disease that typically affects tropical regions worldwide. 51 However, the vector that carries Leishmania is spreading northward into the United 52 States (US). Within a six-month period, three young cutaneous leishmaniasis patients 53 were seen at the Pediatric Infectious Diseases Clinic at The University of Texas 54 55 Southwestern/Children's Health Dallas. None had traveled outside of north Texas. We document their presentations, treatments, and outcomes and compare their 56 management to clinical practice guidelines for leishmaniasis. We also analyzed the 57 sequences of three critical genes in *Leishmania mexicana* isolated from these patients. 58 We found changes that not only distinguish US-based strains from strains found 59 elsewhere, but also differ between US isolates. Monitoring these sequences will allow 60 tracking of genetic changes in parasites over time. Our findings have significant US 61 public health implications as people are increasingly likely to be exposed to what were 62 63 once tropical diseases.

65 **INTRODUCTION**

Leishmaniasis is caused by obligate intracellular parasites of the genus
 Leishmania, which are spread by *Lutzomyia* and *Phlebotomus* sand flies. A spectrum of
 human illness results, including cutaneous, mucocutaneous, and visceral disease.
 Disease manifestations are governed by the infecting parasite species and host immune
 status (1).

71

Generations of medical providers and infectious diseases specialists have been 72 73 taught that leishmaniasis occurs in tropical and subtropical regions, and not the United States (US). Such viewpoints are reflected in published distributions of leishmaniasis 74 (2). However, over time, the sand fly vector's distribution has expanded into previously 75 non-endemic areas (3), and leishmaniasis is well-documented in US animals (4). In 76 addition, multiple articles have described human acquisition of cutaneous leishmaniasis 77 78 within Oklahoma and Texas, where leishmaniasis is now a reportable disease (5). In fact, a cross-sectional observational study indicated that 41/69 cases (59%) of 79 cutaneous leishmaniasis diagnosed from 2007-2017 in Texas were acquired locally 80 81 rather than from travel (6). Nevertheless, it is common for US providers to contemplate a leishmaniasis diagnosis in only patients with a history of foreign birth, travel, or military 82 83 service, which in turn often excludes pediatric patients from consideration.

84

Within a 6-month period, 3 patients with cutaneous leishmaniasis presented to the Pediatric Infectious Diseases (ID) Clinic at the University of Texas Southwestern Medical Center (UTSW)/Children's Health Dallas. These cases reflect this disease's

- changing epidemiology, since clinical isolates from these patients had genetic
- 89 polymorphisms that have been documented in Texan strains of *L. mexicana*.
- 90 Furthermore, we sequenced three *Leishmania* housekeeping genes and identified
- significant differences between our clinical isolates, providing us with a novel
- 92 mechanism to type *L. mexicana* strains. Monitoring these sequences could permit
- 93 documentation of genetic variation among *Leishmania* isolates as this parasite expands
- its geographic range in the US.

96 **RESULTS**

97 Patient presentations

3 cases of cutaneous leishmaniasis acquired in Texas were referred to the
Pediatric ID Clinic at UTSW/Children's Health Dallas over a six month period by their
treating dermatologists. Interestingly, none of these patients' family members had
lesions. Descriptions of these cases follow (Figure 1).

102

103 **Case 1**:

A 0-5 year old girl reported a non-healing nodular lesion on her right jawline that 104 had been present for months. She had not traveled outside north Texas. The lesion had 105 not responded to antibiotic therapy and worsened with steroids. A biopsy showed a 106 granulomatous infiltrate within the dermis, with amastigotes observed inside histiocytes, 107 diagnostic of cutaneous leishmaniasis. Genetic analysis performed at the Centers for 108 Disease Control and Prevention (CDC) demonstrated L. mexicana infection. She was 109 started on 6 mg/kg/day of fluconazole and, with 6 weeks of treatment, the lesion 110 essentially resolved. 111

112

113 Case 2:

A few months later, a 0-5 year-old boy who had no travel history developed a non-healing nodular lesion on his left arm. It did not respond to antibiotics and ulcerated after steroids were administered. He was seen in the ID clinic and had a nearly 2.5 cmdiameter ulcer (**Fig 1A**). Biopsy demonstrated granulomatous inflammation with innumerable amastigotes within histiocytes (**Fig 1B-D**). PCR amplification of parasite

119 DNA performed through the CDC detected *L. mexicana*. He received 6 mg/kg/day of 120 fluconazole and required 10 weeks of therapy for lesion resolution.

121

122 Case 3:

A 0-5 year old boy developed a nodular facial lesion that did not improve with 123 124 antibiotics and worsened with steroids. He had never traveled outside north Texas/southern Oklahoma; however, he had been taken for daily walks at sunset at a 125 lake near his home. A biopsy and genetic sequencing performed at the CDC 126 demonstrated L. mexicana infection, leading to ID referral approximately 1 month after 127 patient 2. He was treated with fluconazole at 6 mg/kg/day, which was increased to 12 128 mg/kg/day after minimal clinical response. When his lesion failed to improve on 129 fluconazole, he was given topical paromomycin, compounded as in Figure 1E (7). After 130 several months, his lesion resolved. 131 132 Genetic sequencing of patient isolates 133

Since there appeared to be an elevated incidence of local *Leishmania* infections, we explored whether there was genetic variability in parasites from clinical samples. With permission from patients 2 and 3, we obtained DNA from lesions for molecular testing (termed Tx2 and Tx3, **Figure 2** and **Supplemental Material**). Unfortunately, a sample from the initial patient (patient 1) was not available for further study. We then proceeded with molecular testing as follows.

140

141 *ITS2 sequencing:*

The CDC sequences the ribosomal RNA-internal transcribed spacer 2 (ITS2) region to identify the infecting *Leishmania* species, since having this information is needed for appropriate therapeutic decisions (7). Texas-specific ITS2 polymorphisms in *L. mexicana* have been described, specifically A \rightarrow C647 and T \rightarrow C649 (8). Our sequence analysis confirmed that these ITS2 polymorphisms were seen in both of our isolates (**Supplemental Figure and Table**).

148

149 Multilocus Sequence Analysis (MLSA):

We next explored whether there was intraspecies variation among isolates using multilocus sequence analysis (MLSA). We selected a panel of 3 housekeeping genes: mannose phosphate isomerase (MPI), malate dehydrogenase (MDH) and 6 phosphogluconate dehydrogenase (6PGD). We used gene-specific primers for amplification and Sanger sequencing to identify synonymous/nonsynonymous SNPs in coding regions. Of note, our primers did not amplify genetic material from uninfected human samples.

157

We found that 6PGD was the most conserved gene, with the least number of SNPs in both isolates. Interestingly, the MDH and MPI genes of Tx2 had significantly diverged from reference strains. In fact, the MDH enzyme in Tx2 was prematurely truncated (by 9 aa at the C terminus) due to transversion 922 ($A \rightarrow T$) (**Figure 2**, **Supplemental Table**). Tx3 also had several SNPs in the MDH and MPI genes that did not match reference strains (**Figure 2**, **Supplemental Table**). Hence, MLSA analysis of

- these three metabolic genes may provide a unique molecular epidemiological
- 165 mechanism to study genetic divergence in *L. mexicana*.

167 DISCUSSION

Here, we have documented 3 cases of cutaneous leishmaniasis due to L. 168 mexicana acquired by pediatric patients within northern Texas. Since our described 169 170 patients had normal immune systems and did not have infected family members, we believe they were individually exposed to sandflies outside their homes. Despite their 171 relatively small number, our cases have significant bearing on US public health 172 initiatives, as the likelihood of US patient exposure to what were formerly 173 geographically-constrained tropical diseases will likely continue to increase as shifting 174 vector distribution and other drivers continue (3). In addition, we have provided a simple 175 means to type strains of *L. mexicana* endemic to the United States. We propose that 176 our methodology can be used to monitor genetic changes in *Leishmania* as the range of 177 178 this parasite expands.

179

Our cases provide multiple therapeutic imputations for treating physicians in the 180 181 US. Per Infectious Disease Society of America (IDSA) guidelines, treating single lesions 182 from non-disseminating cutaneous species is optional, even in pediatric patients (7). 183 However, we treated our patients for cosmetic reasons, since each had facial or large 184 lesions. The referring dermatologists were hesitant to utilize local cryotherapy or 185 brachytherapy (standard for single *L. mexicana*-induced lesions) due to patient age. IDSA guidelines indicate that employing fluconazole is reasonable for US pediatric 186 187 cutaneous leishmaniasis patients (7). Therefore, our patients were initially treated with oral fluconazole, which has a ~50% success rate among all species (9, 10); 2 of our 188 patients responded. Fluconazole is generally well-tolerated, has good oral 189 190 bioavailability, and achieves epidermis/dermis concentrations above plasma levels (11,

12). A dose of 6 mg/kg typically is recommended for pediatric cutaneous leishmaniasis 191 (7). However, for serious fungal infections, many authors propose higher doses (12 192 mg/kg) in children based on fluconazole's lower half-life, higher volume of distribution, 193 more rapid clearance, and minimal side effect profile in pediatric patients, to prevent 194 treatment failure or relapse (13), (14). Combining this literature with our experience, 195 196 initiating higher doses (10-12 mg/kg/day (15)) in younger (< 5-year-old) pediatric leishmaniasis patients may be worthwhile to maximize likelihood and rapidity of 197 response. Furthermore, we note our third patient did not respond to months of 198 199 fluconazole therapy. Consistent with IDSA guidelines, we propose that pediatric leishmaniasis patients be transitioned to alternate agents if they do not begin to respond 200 to high-dose fluconazole in 4-6 weeks (7). Notably, the topical paromomycin employed 201 in patient 3 can be difficult to acquire in the US, as it requires compounding by a willing 202 pharmacy and investigational drug applications, so we did not use it initially in our 203 patients. 204

205

We also determined that our patients' *Leishmania* isolates have undergone 206 207 significant genetic changes that may offer insights into evolutionary biology. Notably, it is now more common for patients in Texas to acquire leishmaniasis locally than from 208 209 travel (5, 6). The CDC has described a specific polymorphism in the ITS2 sequence of 210 L. mexicana in Texas-endemic strains; we replicated these results in our patients' isolates. Furthermore, we provide a mechanism for strain-typing isolates of this newly-211 212 endemic parasite using 3 metabolic genes. Our results demonstrate the power of MLSA 213 analysis as a simple yet important molecular epidemiological tool to study Leishmania

genetic divergence within the US. Since clusters of leishmaniasis cases have been
described, our technique could potentially be used to characterize outbreaks. The large
number of genetic changes that we found using a limited number of isolates suggests
that Texas-specific strains of *L. mexicana* may be under significant evolutionary
selection pressure, which in turn may lead to novel mutations. We plan to continue to
monitor available isolates for this possibility over time.

220

221 Although cases of leishmaniasis certainly have been described in the United States, our case discussions have typically been met with surprise from clinicians and 222 scientists alike. One factor that may lead to this underappreciation of endemicity is that 223 leishmaniasis is a reportable disease in Texas, but not in other states (6). We would 224 argue that leishmaniasis should be a reportable disease nationwide so that its incidence 225 and distribution can be monitored by public health officials. Furthermore, we propose 226 that such information could be collected in conjunction with our strain-typing techniques 227 to characterize ongoing genetic variation in this parasite as its endemic area expands. 228 229 Hence, the cases of cutaneous leishmaniasis described here have significant microbiological, treatment and public health implications. 230

232 METHODS

233 Molecular analysis/Strain typing:

For patient 2 in this report, a clinical sample (termed Tx2) was obtained and briefly 234 cultured at UTSW as promastigotes in Schneider's Insect cell media (Sigma, S9895) 235 supplemented with 20% FBS (GeminiBio, 100-106) and 1% penicillin-streptomycin 236 237 (Sigma, P4333). Time in culture was limited to minimize genetic changes in vitro. DNA was extracted using the DNAeasy Blood and tissue Kit (Qiagen, 69504) according to 238 manufacturer's instructions. For patient 3 (Tx3), we received extracted DNA from the 239 240 CDC (Thanks to Yvonne Qvarnstrom, CDC), which had been generated in a similar manner to Tx2. Extracted DNA was used to amplify the rRNA-internal transcribed 241 spacer (ITS2) region for species identification (Supplemental Figure) and three 242 housekeeping genes: mannose phosphate isomerase (MPI), malate dehydrogenase 243 (MDH) and 6 phosphogluconate dehydrogenase (6PGD) with gene specific primers for 244 245 L. mexicana. Sequences for all primers are in the **Supplemental Table**. The CDS region for these genes was then used for MLSA to explore genetic variation among 246 isolates. Briefly, each gene was amplified with high fidelity DNA polymerase Primestar 247 248 Max (Takara Bio, RO45A) using forward and reverse primers binding in upstream and downstream coding regions, respectively. PCR amplified fragments were Sanger 249 sequenced in the UTSW McDermott Center Sequencing Core facility using Life 250 251 Technologies® Dye Terminator 3.1 chemistry and 3730XL Genetic Analyzers. 252

253 Single nucleotide polymorphism (SNP) analysis:

- Each gene was sequenced bidirectionally using 2 sets of forward (ExtF, IntF) and
- reverse (ExtR and IntR) primers. ExtF and ExtR bind outside of the coding region and
- IntF and IntR bind in the coding region. Due to the sequence variability found in the Tx2
- 257 MPI gene, multiple internal primers were used. SNP analysis was performed using the
- sequence alignment tools EMBOSS needle and Clustal Omega (<u>www.ebi.ac.uk</u>).

259

261 **REFERENCES**

1. Wetzel DM, Phillips MA. Chapter 67: Chemotherapy of protozoal infections:

amebiasis, giardiasis, trichomoniasis, trypanosomiasis, leishmaniasis, and other

protozoal infections. In: Brunton L, editor. Goodman and Gilman's The Pharmacological

Basis of Therapeutics. 13 ed. New York, NY: McGraw-Hill Medical; 2023. p. 1309-24.

266 2. <u>https://www.cdc.gov/dpdx/leishmaniasis/index.html</u>.

3. Gonzalez C, Wang O, Strutz SE, Gonzalez-Salazar C, Sanchez-Cordero V,

268 Sarkar S. Climate change and risk of leishmaniasis in North America: predictions from

ecological niche models of vector and reservoir species. PLoS Negl Trop Dis. 2010 Jan

270 19;4(1):e585.

4. Petersen CA. Leishmaniasis, an emerging disease found in companion animals
in the United States. Top Companion Anim Med. 2009 Nov;24(4):182-8.

5. Wright NA, Davis LE, Aftergut KS, Parrish CA, Cockerell CJ. Cutaneous

leishmaniasis in Texas: A northern spread of endemic areas. J Am Acad Dermatol.

275 2008 Apr;58(4):650-2.

6. McIlwee BE, Weis SE, Hosler GA. Incidence of endemic human cutaneous
leishmaniasis in the United States. JAMA Dermatol. 2018 Sep 1;154(9):1032-9.

278 7. Aronson N, Herwaldt BL, Libman M, Pearson R, Lopez-Velez R, Weina P, et al.

279 Diagnosis and treatment of leishmaniasis: clinical practice guidelines by the Infectious

280 Diseases Society of America (IDSA) and the American Society of Tropical Medicine and

Hygiene (ASTMH). Am J Trop Med Hyg. 2016 Dec 07.

8. de Almeida ME, Steurer FJ, Koru O, Herwaldt BL, Pieniazek NJ, da Silva AJ.

283 Identification of Leishmania spp. by molecular amplification and DNA sequencing

- analysis of a fragment of rRNA internal transcribed spacer 2. J Clin Microbiol. 2011
- 285 Sep;49(9):3143-9.
- 9. Prates FV, Dourado ME, Silva SC, Schriefer A, Guimaraes LH, Brito MD, et al.
- 287 Fluconazole in the treatment of cutaneous leishmaniasis caused by Leishmania
- *braziliensis*: a randomized controlled trial. Clin Infect Dis. 2017 Jan 1;64(1):67-71.
- 10. Alrajhi AA, Ibrahim EA, De Vol EB, Khairat M, Faris RM, Maguire JH.
- 290 Fluconazole for the treatment of cutaneous leishmaniasis caused by *Leishmania major*.
- 291 N Engl J Med. 2002 Mar 21;346(12):891-5.
- 11. Faergemann J. Pharmacokinetics of fluconazole in skin and nails. J Am Acad
- 293 Dermatol. 1999 Jun;40(6 Pt 2):S14-20.
- 12. Faergemann J, Laufen H. Levels of fluconazole in serum, stratum corneum,
- 295 epidermis-dermis (without stratum corneum) and eccrine sweat. Clin Exp Dermatol.
- 296 1993 Mar;18(2):102-6.
- 13. Pacifici GM. Clinical pharmacology of fluconazole in infants and children. Clin
 Med Investig. 2020;5:10.15761.
- 14. Watt K, Benjamin DK, Jr., Cohen-Wolkowiez M. Pharmacokinetics of antifungal
 agents in children. Early Hum Dev. 2011 Mar;87 Suppl 1(Suppl 1):S61-5.
- 301 15. Wade KC, Benjamin DK, Jr., Kaufman DA, Ward RM, Smith PB, Jayaraman B, et
 302 al. Fluconazole dosing for the prevention or treatment of invasive candidiasis in young
 303 infants. Pediatr Infect Dis J. 2009 Aug;28(8):717-23.

304

306 ACKNOWLEDGEMENTS

We are grateful to staff members in the UTSW/Children's Health Dallas Pediatric 307 Infectious Diseases clinic for their flexibility in patient scheduling to ensure that these 308 leishmaniasis patients saw Dr. Wetzel. We thank the Texas Department of Health for 309 discussing these cases with us when we reported them, members of the UT 310 311 Southwestern and global parasitology communities for their support and interest in this experience, and the Pediatric ID Division at UT Southwestern for providing helpful 312 advice. We also thank Dr. Yvonne Qvarnstrom at the CDC for assisting us with 313 acquiring leishmanial DNA from patient 3. Dr. Nepal is funded by American Heart 314 Association Postdoctoral Fellowship 916875. Dr. Wetzel was supported by a Children's 315 Clinical Research Advisory Committee (CCRAC) Early Investigator Award, a 2019 316 Harrington Scholar-Innovator Award, NIH R01 AI146349, a Welch Grant for Chemistry 317 (I-2086) and funds from the UTSW Department of Pediatrics. The funders did not play a 318 role in the writing of this manuscript. Reporting of this small case series (< 3 patients) 319 was exempt from UTSW/Children's Health Dallas-IRB approval. However, the patients 320 in this study provided permission for images to be used and for clinical samples to be 321 322 taken; these activities were approved by the IRBs at both UTSW and Children's Health (STU-2019-0754). 323

324

326 FIGURES

327 Figure 1



E Clinical features	Case 1	Case 2	Case 3
Gender	Female	Male	Male
Race/ethnicity	Hispanic	Hispanic	Caucasian
Travel history	None	None	None
Lesion location	R inferior jaw	L arm	R temple
Lesion size/diameter	1.5 X 1.5 cm	2.5 X 2.5 cm	1 X 2 cm
Duration of	6 months	5 months	4 months
symptoms before			
diagnosis			
Infective species	L. mexicana	L. mexicana	L. mexicana
Initial lab	None performed	Eosinophilia	Mild neutropenia (ANC 1300)
abnormalities*		(AEC 740)	Eosinophilia (AEC 1300)
		Elevated IgE (215)	Mildly low IgG (241)
Treatment	Fluconazole (6	Fluconazole (6	Fluconazole (6 mg/kg X 5 wks; 8 mg/kg
	mg/kg) X 6 wks	mg/kg) X 10 wks	X 3 weeks; 12 mg/kg X 6 wks) →·
			Topical paromomycin (15%
			paromomycin, 12% MBCL in paraffin) X
			10 days on, 10 days off X 3 iterations

Figure 1: Clinical features of patients presented. A-D) Clinical and histopathological

- evaluation of patient 2. A) Approximately 2.5 cm lesion on the left arm clinically
- consistent with cutaneous leishmaniasis. Scale bar = 1 cm. B) Granulomatous
- inflammation with numerous histiocytes (100x magnification, H&E). Sample shared from
- 333 Sagis Diagnostics, Houston, TX. C) Small, round amastigotes are visible within
- histiocytes in the reticular dermis (500x magnification, H&E). **D)** Amastigotes within
- histiocytes with visible kinetoplasts at arrowheads (1000x magnification, oil immersion,
- H&E). E) Patient demographics, signs and symptoms, and laboratory findings. *Normal
- 337 studies in Case 2 included CBC, remainder of differential, C-reactive protein, and
- 338 chemistries including liver function panel. Normal studies in Case 3 included CBC,
- remainder of differential, C-reactive protein, chemistries including liver function panel,
- 340 IgA, IgM, and IgE. All laboratory abnormalities resolved after treatment. ANC, Absolute
- neutrophil count. AEC, Absolute eosinophil count.

343 Figure 2

344 **A**

	MPI		MDH		PGD	
Substitution						
	1x2	1x3	Ix2	1x3	Tx2	1x3
Transitions	252 (G→A)	592 (A→G)	185 (T→C)	523 (A→G)	990 (A→G)	990 (A→G)
	417 (C→T)	612 (T→C)	223 (A→G)			
	501 (A→G)	661 (T→C)	226 (C→T)			
	504 (C→T)		300 (T→C)			
	529 (A→G)		332 (1→C)			
	592 (A→G)		515 (A→G)			
	$612(T \rightarrow C)$		523 (A→G)			
	661 (I→C)		846 (C \rightarrow I)			
	693 (A→G)		868 (A→G)			
	$711(1\rightarrow C)$		869 (I→C)			
	$720 (G \rightarrow A)$					
	1148 (A→G)					
Transversion	$\frac{1182}{492} (G \rightarrow A)$		494 (T . A)		720 (C T)	
Transversion	$403 (A \rightarrow I)$		$104(1 \rightarrow A)$	292 (A→C)	729 (G→T)	
	$493 (A \rightarrow 1)$		292 (A→C) 279 (T→C)			
	$545 (C \rightarrow G)$		$370(1\rightarrow G)$			
	$603 (C \rightarrow A)$		$922(A \rightarrow 1)$			
	$870 (C \rightarrow C)$		940 (T→A)			
	$1032(C \rightarrow C)$					
	1002 (0-0)					

345

346

В



347

348 Figure 2. Genetic analysis of clinical isolates. A) SNPs reported after MLSA

analysis. The nonsynonymous SNPs are in bold. **B)** Venn diagram showing SNPs

reported on genes analyzed by MLSA.

352 SUPPLEMENTAL MATERIAL

353

- 354 Supplemental Methods, Results and Discussion:
- Additional specific details regarding genetic sequencing of the clinical isolates from
- these patients are described below. Of interest, this analysis can be done after sampling
- lesions with a flocked nylon swab, which provides a less invasive means of diagnosis in
- 358 children. All sequences described in this manuscript have been submitted to TriTryp DB
- 359 (<u>TriTrypDB</u>).

360

ITS2: We performed sequence analysis on the rRNA-internal transcribed spacer 2
 (ITS2) region, which shows a previously reported Texas-specific polymorphism, C647
 and C649, on both Tx2 and Tx3. For this analysis, FJ948434 was used as a reference
 strain. However, alignments of the FJ948434 ITS2 sequence with 25 publicly available
 non-US *L. mexicana* ITS2 sequences were identical. Isolates' ITS2 sequences are
 shown in the Supplemental Figure, and primer sequences are contained in the
 Supplemental Table.

368

Metabolic enzymes: For the three metabolic enzymes sequenced, *Leishmania mexicana* MHOM/GT/2001/U1103 (Guatemala) was used as a reference strain, since it
 is the *L. mexicana* strain with the most widely available genomic sequence (1).

372

MDH: SNP analysis in the CDS of the MDH gene showed a total of 15 SNPs in Tx2. We identified nine base transitions: 185 (T \rightarrow C), 223 (A \rightarrow G), 226 (C \rightarrow T), 300 (T \rightarrow C), 332 (T \rightarrow C), 515 (A \rightarrow G), 523 (A \rightarrow G), 846 (C \rightarrow T), 868 (A \rightarrow G), 869 (T \rightarrow C), and five base

376	transversions, 184 (T \rightarrow A), 292 (A \rightarrow C), 378 (T \rightarrow G), 922 (A \rightarrow T), 946 (T \rightarrow A). Tx3 had
377	two SNPs, a base transition at 523 (A \rightarrow G) and a transversion at 292 (A \rightarrow C). We note
378	that SNPs 184 (T \rightarrow A), 185 (T \rightarrow C), 223 (A \rightarrow G), 226 (C \rightarrow T), 515 (A \rightarrow G), 523 (A \rightarrow G),
379	868 (A \rightarrow G), 869 (T \rightarrow C) were nonsynonymous and resulted in amino acid changes
380	(Figure 2, Supplemental Table). Of particular interest, MDH in Tx2 was prematurely
381	truncated (by 9 aa at the C terminus) due to transversion 922 (A \rightarrow T). However, this
382	truncation would not be expected to affect its enzymatic function (2).
383	
384	PGD: Similarly, we identified 2 SNPs on coding region of PGD gene of Tx2,
385	transversion at 729 (G \rightarrow T) and single transition 990 (A \rightarrow G). Tx3 had a single base
386	transition at 990 (A \rightarrow G).
387	
388	<i>MPI:</i> The MPI gene for the Tx3 isolate had 3 base transitions, 592 (A \rightarrow G), 612 (T \rightarrow C),
389	661 (T \rightarrow C). On the other hand, for Tx2, the MPI gene had 20 SNPs: transitions 252
390	$(G \rightarrow A)$, 417 $(C \rightarrow T)$, 501 $(A \rightarrow G)$, 504 $(C \rightarrow T)$, 529 $(A \rightarrow G)$, 592 $(A \rightarrow G)$, 612 $(T \rightarrow C)$, 661
391	(T \rightarrow C), 693 (A \rightarrow G), 711 (T \rightarrow C), 720 (G \rightarrow A), 1148 (A \rightarrow G), 1182 (G \rightarrow A) and
392	transversions: 483 (A \rightarrow T), 493 (A \rightarrow T), 545 (C \rightarrow G), 605 (C \rightarrow A), 663 (C \rightarrow G), 870
393	(C→A), 1032 (C→G). SNPs 529 (A→G), 545 (C→G), 592 (A→G), 605 (C→A), 661

(T \rightarrow C), 663 (C \rightarrow G), 1148 (A \rightarrow G) were nonsynonymous.

395

397 Supplemental Figure

398

399 FJ948434.1 ATACACACATGTGCACTCTCCTTTGTGTGGGGTGCGCGCGC	660 224 224
--	-------------------

403

- 404 **Supplemental Figure.** Sequences of the relevant ITS2 region in a representative non-
- US reference strain (FJ948434.1), compared to Tx2 and Tx3.

406

408 Supplemental Table

-	_	-
Λ	n	a
4	U	3

Gene	Accession number	Amplicon size (bp)	CDS length (bp)	Location	Primer sequence
ITS2		Variable	N/A	18S ribosome	ITS2.F: GCATGCCATATTCTCAGTGTC ITS2.R: GGCCAACGCGAAGTTGAATTC ITS2.R1: GAATTCTCGTTTTGGTTTTTTG
Glucose-6- phosphate dehydrogenase (<i>g6pdh)</i>	XM_003879281.1	1700	1440	Chr 34	ExtF: TTACTGGCGCTTAGTCCCATCATA ExtR: TAAGAGCGGAATCGGGTGC IntF: GCAGGCAACTATCTGTCAGAGAA IntR: ATGTTGAGCGAGGGCGCTG
Malate dehydrogenase (<i>mdh</i>)	XM_003878549.1	1166	951	Chr 33	ExtF: TGCCGTACAATCCATCTCGC ExtR: AACGACGCCGCATCATTGTG IntF: ATCATCAGCAACCCTGTCAACAGC IntR: TAACGTCGTACGGGCTTGC
Mannose phosphate isomerase (<i>mpi</i>)	XM_003879281	1471	1266	Chr 31	ExtF: TCTGGGTTGTGTAGTAGCGTC ExtR: AATTCGCCTGCCACTGTG IntF: TCCAGAGCTGGCTGAGCTTGTAG IntR: CATACACGGTCGTCATCATAGTC SeqF1: CTTTGAGGCACTCTGCTGC SeqF2: GACTATGATGACGACCGTGTATG SeqR1: CGTCGTATCGTTCACCTTGGCAG SeqR1: CGTCAATGTTGAAGGAAACTCGGT

410

411 Supplemental Table. Genes and primer sequences used for MLSA analysis.

412

414 SUPPLEMENTAL REFERENCES

- 1. Rogers MB, Hilley JD, Dickens NJ, Wilkes J, Bates PA, Depledge DP, et al.
- 416 Chromosome and gene copy number variation allow major structural change
- 417 between species and strains of Leishmania. Genome Res. 2011
- 418 Dec;21(12):2129-42.
- 419 2. Leroux A, Fleming-Canepa X, Aranda A, Maugeri D, Cazzulo JJ, Sánchez MA,
- 420 and Nowicki C. Functional characterization and subcellular localization of the
- 421 three malate dehydrogenase isozymes in Leishmania spp. Mol Biochem
- 422 Parasitol. 2006: 149(1):74-85.